Related Experiment Video
Updated: Feb 28, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Cardiac Complications, Earlier Treatment, and Initial Disease Severity in Kawasaki Disease
Joseph Y Abrams1, Ermias D Belay1, Ritei Uehara2
1Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
Insights
Early treatment for Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) is not linked to higher cardiac risks. Initial disease severity, not early IVIG, explains the observed associations in KD patients.
Area of Science:
- Pediatrics
- Immunology
- Cardiology
Background:
- Kawasaki disease (KD) is a leading cause of acquired heart disease in children.
- Concerns exist regarding potential cardiac complications associated with early treatment for KD.
Purpose of the Study:
- To investigate whether higher observed risks of cardiac complications in early-treated KD patients are due to confounding by initial disease severity.
- To clarify the true effect of early intravenous immunoglobulin (IVIG) treatment on cardiac outcomes in KD.
Main Methods:
- Analysis of Japanese nationwide KD surveys (1997-2004) involving 48,310 patients.
- Used receipt of additional IVIG or treatments as proxies for initial disease severity.
- Employed logistic modeling and stratification to assess associations between early (days 1-4) vs. late (days 5-10) IVIG treatment and cardiac complications.
Main Results:
- Unadjusted analysis showed higher risks of cardiac complications with earlier IVIG treatment.
- Stratification by additional treatment and logistic modeling controlling for it removed this association.
- Early IVIG treatment (days 1-4) demonstrated a protective effect against major cardiac complications (OR, 0.90; 95% CI, 0.80-1.00) after adjustment.
Conclusions:
- Observed higher cardiac complication risks in early-treated KD patients are likely attributable to underlying disease severity, not the early treatment itself.
- Early IVIG treatment remains a recommended and beneficial strategy for managing Kawasaki disease.
Objectives:
To assess if observed higher observed risks of cardiac complications for patients with Kawasaki disease (KD) treated earlier may reflect bias due to confounding from initial disease severity, as opposed to any negative effect of earlier treatment.
Study Design:
We used data from Japanese nationwide KD surveys from 1997 to 2004. Receipt of additional intravenous immunoglobulin (IVIG) (data available all years) or any additional treatment (available for 2003-2004) were assessed as proxies for initial disease severity. We determined associations between earlier or later IVIG treatment (defined as receipt of IVIG on days 1-4 vs days 5-10 of illness) and cardiac complications by stratifying by receipt of additional treatment or by using logistic modeling to control for the effect of receiving additional treatment.
Results:
A total of 48 310 patients with KD were included in the analysis. In unadjusted analysis, earlier IVIG treatment was associated with a higher risk for 4 categories of cardiac complications, including all major cardiac complications (risk ratio, 1.10; 95% CI, 1.06-1.15). Stratifying by receipt of additional treatment removed this association, and earlier IVIG treatment became protective against all major cardiac complications when controlling for any additional treatment in logistic regressions (OR, 0.90; 95% CI, 0.80-1.00).
Conclusions:
Observed higher risks of cardiac complications among patients with KD receiving IVIG treatment on days 1-4 of the illness are most likely due to underlying higher initial disease severity, and patients with KD should continue to be treated with IVIG as early as possible.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

